BRCA & Ovarian Cancer Risk: What Carriers Need to Know

01 / 09

What is the ovarian cancer risk for BRCA carriers?

People who inherit a pathogenic BRCA1 variant face a 39–58% lifetime risk of ovarian cancer, while BRCA2 carriers face 13–29%—compared with about 1.1% in the general population.

In hereditary-cancer guidance, “ovarian cancer” generally includes epithelial ovarian, fallopian tube, and primary peritoneal cancers. These are population ranges, not personal forecasts; age, family history, the specific variant, and other factors can shift risk. ^[1,2,10]

Lifetime ovarian, fallopian tube, and primary peritoneal cancer risk by BRCA status.
Group	Lifetime risk	How to read it
BRCA1 pathogenic variant	39–58%	Highest of the three ranges. ^[1,2]
BRCA2 pathogenic variant	13–29%	Elevated, with later average onset. ^[1,2]
General population	About 1.1%	Baseline estimate, not zero risk. ^[1]

For broader gene context, read the BRCA gene overview.

02 / 09

Why ovarian cancer risk is different: the screening gap

Breast MRI can begin around age 25 for many BRCA carriers, with mammography commonly added around age 30. Ovarian cancer has no equivalent early-detection safety net.

Breast cancer

Established surveillance

Gene- and age-specific MRI and mammography can find many cancers earlier. ^[4]

Ovarian cancer

No proven survival-improving screen

Transvaginal ultrasound and CA-125 have not been proven to detect disease early enough to improve long-term survival. ^[5,7]

NCI states that no effective ovarian cancer screening methods are known. TVUS and CA-125 may still be discussed in selected circumstances, but false reassurance, false positives, and late detection limit them. This is why prevention through appropriately timed risk-reducing salpingo-oophorectomy—not routine screening—is the evidence-based standard for many BRCA carriers. ^[4,5,7]

03 / 09

BRCA1 vs. BRCA2: how ovarian cancer risk differs

BRCA1 carries the higher risk and BRCA1-associated ovarian cancer tends to occur roughly 8–10 years earlier than BRCA2-associated disease. That timing difference helps shape gene-specific prevention windows.

BRCA1

39–58% lifetime risk. More strongly associated with high-grade serous ovarian, fallopian tube, and primary peritoneal carcinoma; risk begins rising earlier.

BRCA2

13–29% lifetime risk. Still substantially elevated, but average onset is later, allowing RRSO to be discussed at a later age in many families.

These are associations, not rules for every carrier or tumor. See the fuller guide to BRCA1 vs. BRCA2 differences. ^[1,2,4,6]

04 / 09

RRSO: timing and what to expect

NCCN guidance recommends discussing risk-reducing salpingo-oophorectomy after childbearing—typically ages 35–40 for BRCA1 and 40–45 for BRCA2, reflecting the later average onset associated with BRCA2.

BRCA1

35–40

Discuss surgery sooner because ovarian cancer risk rises earlier.

BRCA2

40–45

Later average onset supports a later discussion for many carriers.

RRSO removes both fallopian tubes and ovaries and lowers tubo-ovarian cancer risk by about 90%, but does not eliminate it; a small primary peritoneal cancer risk remains. Earlier studies also reported lower premenopausal breast cancer risk after RRSO, but estimates vary and ovarian-cancer prevention is the principal rationale. ^[4,6,7,10]

05 / 09

Other ways risk may be reduced

Oral contraceptive use for five or more years has been associated with about a 50% reduction in ovarian cancer risk, including among BRCA carriers. It is a risk modifier—not a screen or a replacement for RRSO.

Evidence and limitations for ovarian cancer risk-reduction options.
Option	Evidence signal	Important limit
Oral contraceptives	About 50% lower risk after 5+ years in observational data.	Benefits and breast, clotting, and other risks require individualized review. ^[8,9,10]
Tubal ligation	Some observational studies report substantial reduction, up to 67%.	Not equivalent to RRSO and not sufficient prevention for a BRCA carrier. ^[9]
Salpingectomy with delayed oophorectomy	An emerging staged strategy under study.	Cancer-prevention effectiveness is not yet established as equivalent to standard RRSO. ^[4,7]

There is no medication approved as a stand-alone substitute for RRSO in BRCA carriers. These choices concern risk reduction; none screens for or diagnoses ovarian cancer.

06 / 09

Why knowing BRCA status matters—and how test scope differs

Without a reliable ovarian screening safety net, identifying inherited risk can open the prevention pathway. But a three-variant consumer report, a hereditary cancer panel, and whole-genome sequencing do not ask the same question.

01
Review the family record
Document ovarian, fallopian tube, primary peritoneal, breast, pancreatic, prostate, and male breast cancers on both sides of the family.
02
Meet with a genetics professional
A counselor can assess eligibility, discuss possible results, and identify the most informative relative to test first.
03
Match the test to the question
Use targeted testing when a familial variant is known; consider a clinical multigene panel when the cause is unknown.
04
Confirm before acting
A positive, uncertain, or negative consumer or broad-sequencing result may require clinical confirmation or additional testing.

Comparison of single-gene, multigene, direct-to-consumer, and whole-genome approaches.
Approach	Scope	Best understood as
Single-gene / familial variant	One gene or one known family variant	Focused and clinically efficient when the target is known.
Hereditary cancer panel	BRCA1/2 plus a selected gene set	Clinically focused; genes and validated variant classes vary.
Limited DTC report	A fixed list that may include only a few founder variants	A negative result does not exclude other pathogenic variants. ^[12]
~30× whole-genome sequencing	Genome-wide data across coding and non-coding regions	A much broader inherited-health foundation; report scope, coverage, confirmation, and interpretation still matter.

One genome. A broader inherited-health view.

HLI's $599 service uses approximately 30× whole-genome sequencing and AI-assisted interpretation to help make a much broader genome-wide dataset understandable.

The service includes a cancer risk assessment covering BRCA1 and BRCA2 among other genes, plus cardiovascular and pharmacogenomic findings and one year of the Human Longevity AI app. This broader scope is not greater diagnostic certainty and should not be treated as a definitive BRCA test.

See what the $599 genome service includes

Learn who should get BRCA testing, or review the $599 whole-genome service.

07 / 09

Inheritance affects the whole family

50%

A pathogenic BRCA1 or BRCA2 variant is inherited in an autosomal dominant pattern. Each child of a carrier has a 50% chance of inheriting that variant, independently for each pregnancy. People of any sex can inherit and pass it on. ^[1,10]

BRCA-related risk is not limited to ovarian and breast cancer; prostate, pancreatic, and male breast cancer can also matter. Ashkenazi Jewish ancestry is associated with an estimated carrier prevalence near 1 in 40, but ancestry-specific founder testing can miss other variants. A counselor can help identify who in a family should test first and how cascade testing should proceed. ^[1,10,11]

08 / 09

Frequently asked questions

Q1What percentage of BRCA1 carriers get ovarian cancer?

Estimates place lifetime ovarian cancer risk at 39–58% for people with a pathogenic BRCA1 variant, compared with about 1.1% in the general population. Individual risk varies with family history, age, and the specific variant. ^[1,2,3]

Q2Can you screen for ovarian cancer if you have BRCA?

No reliable screening method has been proven to detect ovarian cancer early enough to improve survival. Transvaginal ultrasound and CA-125 may be considered in selected situations, but they are not substitutes for discussing evidence-based prevention. ^[4,5,7]

Q3Should I have my ovaries removed if I have BRCA?

NCCN guidance supports discussing RRSO after childbearing: generally ages 35–40 for BRCA1 and 40–45 for BRCA2. This irreversible decision should be personalized with a genetic counselor and gynecologic oncologist. ^[4,6,10]

Q4What is the difference between BRCA1 and BRCA2 ovarian cancer risk?

BRCA1 is associated with a 39–58% lifetime ovarian cancer risk; BRCA2 with 13–29%. BRCA1-associated disease also tends to occur earlier, helping explain why recommended risk-reducing surgery is discussed sooner. ^[1,2,4]

Q5Does BRCA2 cause ovarian cancer?

A pathogenic BRCA2 variant increases lifetime ovarian cancer risk to 13–29%, versus about 1.1% in the general population. It raises susceptibility; it does not mean cancer is present or inevitable. ^[1,2]

Q6What is the strongest known inherited risk factor for ovarian cancer?

Pathogenic inherited variants—especially in BRCA1 and BRCA2—are among the strongest known ovarian cancer risk factors. Other hereditary cancer genes can also matter, so assessment should not stop automatically at BRCA1 and BRCA2. ^[1,10]

09 / 09

References and review notes

Sources and product context were reviewed September 28, 2026. NCCN guidance, risk estimates, and service scope can change; this page should be reviewed at least every six months.